Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28978067 | 0.86 | RXFP1 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28610512 | 0.84 | STS (0.56) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL28611806 | 0.80 | STS (0.52) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL28622743 | 0.80 | STS (0.52) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL21577602 | 0.79 | STS (0.49) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL21577641 | 0.77 | EPHX2 (0.57) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL23022525 | 0.76 | EED (0.43) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL8602574 | 0.76 | TGFBR1 (0.54) | STSALDH1A1EPHX2GPR119TGFBR1 | |
| SCHEMBL21597765 | 0.75 | EPHX2 (0.55) | STSALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL28607569 | 0.74 | STS (0.45) | STSALDH1A1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | STS 4429/4885ALDH1A1 2935/4885MEN1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.